HER2-directed CAR-NK

HER2-directed CAR-NK is a **HER2-targeting chimeric antigen receptor natural killer cell therapy** being investigated for HER2-positive malignancies. It consists of NK cells, including engineered NK-92 cells in some programs, modified to express a CAR with an extracellular HER2-binding domain and intracellular activation domains such as CD3 zeta and CD28, enabling antigen-directed recognition and killing of HER2-expressing tumor cells. The modality is being explored as an allogeneic or off-the-shelf cell-based immunotherapy with potential advantages versus CAR-T approaches, including lower risk of graft-versus-host disease and cytokine release syndrome. A specifically named example is **NK-92/5.28.z**, which has been studied in glioblastoma, while HER2-directed CAR NK-92 cells have also been investigated in neuroblastoma; broader literature also discusses development concepts in HER2-positive breast, ovarian, gastric, and gastroesophageal cancers.

Other names

HER2-directed CAR-NKHER-2-directed CAR-NKHER 2-directed CAR-NKHER2-directed CAR NK-92 cellsHER-2-directed CAR NK-92 cellsHER 2-directed CAR NK-92 cellsHER2 CAR-NKHER-2 CAR-NKHER 2 CAR-NKHER2-specific CAR-NK cellsHER-2-specific CAR-NK cellsHER 2-specific CAR-NK cellsHER2-targeted CAR-NK cellsHER-2-targeted CAR-NK cellsHER 2-targeted CAR-NK cells